Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)
CUSIP: 034569103
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 41,587,315
- Total 13F shares
- 22,570,347
- Share change
- +15,226,613
- Total reported value
- $37,311,560
- Price per share
- $1.68
- Number of holders
- 15
- Value change
- +$24,974,043
- Number of buys
- 8
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 034569103?
CUSIP 034569103 identifies ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 034569103:
Top shareholders of ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| 22NW, LP |
13F
|
Company |
13%
|
5,366,290
|
$10,356,940 | — | 30 Sep 2024 | |
| MANGROVE PARTNERS IM, LLC |
13D/G
|
— |
6.2%
|
2,525,252
|
$2,979,797 | $0 | 31 Dec 2024 | |
| LVW Advisors, LLC |
13F
|
Company |
1.5%
|
641,039
|
$1,237,206 | — | 30 Sep 2024 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.2%
|
511,073
|
$986,371 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.96%
|
399,219
|
$770,493 | — | 30 Sep 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.38%
|
157,862
|
$304,675 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.37%
|
154,036
|
$297,289 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.21%
|
87,790
|
$169,474 | — | 30 Sep 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
18,978
|
$36,628 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.01%
|
3,905
|
$7,536 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
2,694
|
$5,199 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
763
|
$1,473 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
76
|
$147 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
9
|
$17 | — | 30 Sep 2024 | |
| Simon Allen |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
70,246
|
— | — | 09 Dec 2022 | |
| Karah Herdman Parschauer |
3/4/5
|
Director |
—
class O/S missing
|
30,425
|
— | — | 21 Apr 2022 |
Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) as of Q4 2024
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.